The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis
Open accessAbstract
Aim: The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily because glycaemic efficacy is dependent on kidney function. We performed a systematic review and meta‐analysis to assess the efficacy and safety of SGLT2 inhibitors in patients with T2DM and CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 . Materials and methods: We searched MEDLINE, EMBASE and the Cochrane Library until 7 August 2018 and websites of the US, European and Japanese regulatory authorities until 27 July 2018 for data from randomized controlled trials of SGLT2 inhibitors that included reporting of effects on biomarkers, cardiovascular, renal or safety outcomes in individuals with T2DM and CKD. Random effects models and inverse variance weighting were used to calculate relative risks with 95% confidence intervals. Results: Data were obtained from 27 studies with up to 7363 participants involved. In patients with T2DM and CKD, SGLT2 inhibitors lowered glycated haemoglobin (−0.29%; 95% CI, −0.39 to −0.19) as well as blood pressure, body weight and albuminuria. SGLT2 inhibition reduced the risk of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (RR, 0.81; 95% CI, 0.70‐0.94) and heart failure (RR, 0.61; 95% CI, 0.48‐0.78), without a clear effect on all‐cause mortality (HR, 0.86; 95% CI, 0.73‐1.01). These agents also attenuated the annual decline in eGFR slope (placebo‐subtracted difference of 1.35 mL/1.73 m 2 /y; 95% CI, 0.78‐1.93) and reduced the risk of the composite renal outcome (HR, 0.71; 95% CI, 0.53‐0.95). There was no evidence of additional risks with SGLT2 inhibition in CKD beyond those already known for the class, although heterogeneity was observed across individual agents for some safety outcomes. Conclusion: Currently available data suggest that, despite only modest reductions in glycated haemoglobin, SGLT2 inhibitors reduce the risk of cardiovascular and renal outcomes in patients with T2DM and CKD, without clear evidence of additional safety concerns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors are not currently indicated for people with an eGFR lower than 45 ml/min per 1•73 m² in most countries, largely because of insufficient glycaemic efficacy.29”
From SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (2019) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 3×
“HbA1c for individuals with CKD was modest in comparison to that previously reported for the general T2DM population.(2,3,89) This was”
BackgroundResultEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Self-citationEffects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 556
Gupta, S., Dominguez, M., & Golestaneh, L. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.03.004 · Cited by 373
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 276
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Bailey, C. J., Day, C., & Bellary, S. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01442-z · Cited by 273
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.094 · Cited by 253
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Talha, K. M., Anker, S. D., & Butler, J. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0030 · Cited by 209
Euglycemic diabetic ketoacidosis: A missed diagnosis
Nasa, P., CHAUDHARY, S. K., Shrivastava, P. K., & Singh, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.514 · Cited by 180
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-5938 · Cited by 171
Self-citationStempniewicz, N., Vassalotti, J. A., Cuddeback, J. K., Ciemins, E., Storfer-Isser, A., Sang, Y., Matsushita, K., Ballew, S. H., Chang, A. R., Levey, A. S., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2715 · Cited by 157
Renal effects of SGLT2 inhibitors
Nespoux, J., & Vallon, V. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000584 · Cited by 145
Fenta, E. T., Eshetu, H. B., Kebede, N., Bogale, E. K., Zewdie, A., Kassie, T. D., Anagaw, T. F., Mazengia, E. M., & Gelaw, S. S. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01202-x · Cited by 169
SGLT2-inhibitors; more than just glycosuria and diuresis
Fathi, A., Vickneson, K., & Singh, J. S. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10038-w · Cited by 109
Pelletier, R., Ng, K., Alkabbani, W., Labib, Y., Mourad, N., & Gamble, J. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098621989134 · Cited by 93
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Mascolo, A., Napoli, R. D., Balzano, N., Cappetta, D., Urbanek, K., Angelis, A. D., Scisciola, L., Meo, I. D., Sullo, M. G., Rafaniello, C., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1010693 · Cited by 95
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01163-9 · Cited by 88
Pan, H., Chen, J., Chen, H., Yeh, F.-Y., Huang, T. T.-M., Sun, C., Wang, S., Wei, J. C., & Wu, V. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.50050 · Cited by 82
Mitochondrial Dysfunction and Heart Disease: Critical Appraisal of an Overlooked Association
Bisaccia, G., Ricci, F., Gallina, S., Baldassarre, A. D., & Ghinassi, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020614 · Cited by 85
Iskander, C., Cherney, D. Z. I., Clemens, K. K., Dixon, S. N., Harel, Z., Jeyakumar, N., McArthur, E., Muanda, F. T., Parikh, C. R., Paterson, J. M., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191283 · Cited by 76
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Ala, M. (2021) · Endocrinology · doi:10.1210/endocr/bqab157 · Cited by 71
Li, N., Lv, D., Zhu, X., Wei, P., Gui, Y., Liu, S., Zhou, E., Zheng, M., Zhou, D. F., & Zhang, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.728089 · Cited by 70
Mark, P. B., Sarafidis, P. A., Ekart, R., Ferro, C. J., Balafa, O. C., Fernández‐Fernández, B., Herrington, W. G., Rossignol, P., Vecchio, L. D., Valdivielso, J. M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad112 · Cited by 76
Bray, J. J. H., Foster-Davies, H., & Stephens, J. W. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108368 · Cited by 64
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
Cherney, D. Z. I., Ferrannini, E., Umpierrez, G. E., Peters, A. L., Rosenstock, J., Carroll, A. K., Lapuerta, P., Banks, P. L., & Agarwal, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14513 · Cited by 65
Madero, M., Chertow, G. M., & Mark, P. B. (2024) · Kidney Medicine · doi:10.1016/j.xkme.2024.100851 · Cited by 69
Kushner, P. R., Khunti, K., Cebrián, A., & Deed, G. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02957-z · Cited by 77
Siao, W.-Z., Lin, T., Huang, J., TSAI, C., & Jong, G. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221098168 · Cited by 67
SGLT2 Inhibitors: The Sweet Success for Kidneys
Dharia, A., Khan, A. A., Sridhar, V. S., & Cherney, D. Z. I. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102135 · Cited by 62
SGLT2 inhibitors: a narrative review of efficacy and safety
Nelinson, D. S., Sosa, J. M., & CHILTON, R. J. (2021) · Journal of Osteopathic Medicine · doi:10.1515/jom-2020-0153 · Cited by 58
Shao, S., Chang, K., Lin, S.-J., Chien, R., Hung, M., Chan, Y., Yang, Y. K., & Lai, E. C. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0990-2 · Cited by 55
Chewcharat, A., Prasitlumkum, N., Thongprayoon, C., Bathini, T. J., Medaura, J. A., Vallabhajosyula, S., & Cheungpasitporn, W. (2020) · Medical Sciences · doi:10.3390/medsci8040047 · Cited by 52
Ujjawal, A., Schreiber, B., & Verma, A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221090001 · Cited by 53
Xu, C., Ha, X., Yang, S., Tian, X., & Jiang, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1232790 · Cited by 60
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Škrabić, R., Kumrić, M., Vrdoljak, J., Rušić, D., Skrabic, I., Vilović, M., Martinović, D., Duplancic, V., Kurir, T. T., & Božić, J. (2022) · Biomedicines · doi:10.3390/biomedicines10102458 · Cited by 51
Cherney, D. Z. I., Ferrannini, E., Umpierrez, G. E., Peters, A. L., Rosenstock, J., Powell, D. R., Davies, M. J., Banks, P. L., & Agarwal, R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15019 · Cited by 51
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Mottl, A. K., Alicic, R. Z., Argyropoulos, C., Brosius, F. C., Mauer, M. S., Molitch, M. E., Nelson, R. G., Perreault, L., & Nicholas, S. B. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.010 · Cited by 60
Tian, Q., Guo, K., Deng, J., Zhong, Y., & Yang, L. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17115 · Cited by 51
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis
Caravaca‐Fontán, F., Stevens, K., Padrón, M., Huerta, A., Montomoli, M., Villa, J., González, F., Vega, C., Mendoza, M. L., Fernández, L., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad175 · Cited by 51
Lee, O. Y. A., Wong, A. N. N., Ho, C. Y., Tse, K. W., Chan, A. Z., Leung, G., Kwan, Y. W., & Yeung, M. H. Y. (2024) · Antioxidants · doi:10.3390/antiox13060751 · Cited by 58
Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem
Garf, S. L., Nègre, V., Anty, R., & Gual, P. (2021) · Biomedicines · doi:10.3390/biomedicines9121915 · Cited by 47
The future of new drugs for diabetes management
Bailey, C. J., & Day, C. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107785 · Cited by 48
Baviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Genovese, S., Caruso, I., & Giorgino, F. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01572-y · Cited by 48
Piccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 49
Milder, T. Y., STOCKER, S. L., Day, R. O., & Greenfield, J. R. (2020) · Drug Safety · doi:10.1007/s40264-020-01010-6 · Cited by 43
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
Zhou, X., Ye, X., Guo, X., Liu, D., Xu, J., Hu, F., Zhai, Y., Gao, Y., Xu, X., Dong, Z., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.766125 · Cited by 43
Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Chen, J., Pan, H., Shiao, C., Chuang, M., See, C. Y., Yeh, T.-H., Yang, Y., Chu, W.-K., & Wu, V. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02035-8 · Cited by 44
Toyama, T., Kitagawa, K., Oshima, M., Kitajima, S., Hara, A., Iwata, Y., Sakai, N., Shimizu, M., Hashiba, A., Furuichi, K., et al. (2020) · BMC Nephrology · doi:10.1186/s12882-020-02121-z · Cited by 45
Self-citationProtective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
Fontes‐Carvalho, R., Santos‐Ferreira, D., Raz, I., Marx, N., Ruschitzka, F. T., & Cosentino, F. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab034 · Cited by 42
Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox
Dao, M., & François, H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.720734 · Cited by 49
Nevola, R., Alfano, M., Pafundi, P. C., Brin, C., Gragnano, F., Calabrò, P., Adinolfi, L. E., Rinaldi, L., Sasso, F. C., & Caturano, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303106 · Cited by 43
Packer, M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107647 · Cited by 42
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 42
SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
Thomas, M. C., Neuen, B. L., Twigg, S. M., Cooper, M. E., & Badve, S. V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0005 · Cited by 45
Self-citationJohansen, M. E., & Argyropoulos, C. (2020) · Clinical Cardiology · doi:10.1002/clc.23508 · Cited by 39
Lee, B. S., Holstein‐Rathlou, N., Sosnovtseva, O. V., & Sørensen, C. M. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00147.2023 · Cited by 39
The vascular complications of diabetes: a review of their management, pathogenesis, and prevention
Meir, J., Huang, L., Mahmood, S., Whiteson, H. Z., Cohen, S., & Aronow, W. S. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2279533 · Cited by 43
Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13743 · Cited by 37
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Tharmaraja, T., Ho, J. S. Y., Sia, C., Lim, N.-A., Chong, Y. F. V., Lim, A. Y. L., Rathakrishnan, R., Yeo, L. L. L., Sharma, V. K., & Tan, B. Y. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221086996 · Cited by 38
Cao, H., Rao, X., Jia, J., Yan, T., & Li, D. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01989-7 · Cited by 39
Kinguchi, S., Wakui, H., Ito, Y., Kondo, Y., Azushima, K., Osada, U. N., Yamakawa, T., Iwamoto, T., Yutoh, J., Misumi, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0912-3 · Cited by 36
Zheng, C., Lin, M., Chen, Y., Xu, H., Yan, L., & Dai, H. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01272-z · Cited by 38
SKOLNIK, N., & Style, A. J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01050-w · Cited by 40
Pollock, C. A., James, G., Sánchez, J. J. G., Carrero, J. J., Arnold, M., Lam, C. S. P., Chen, H., NOLAN, S. T., Pecoits‐Filho, R., & Wheeler, D. C. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac168 · Cited by 35
Chauhan, K., Nadkarni, G. N., Fleming, F., McCullough, J. R., He, C., Quackenbush, J. F., Murphy, B. T., Donovan, M. J., Coca, S. G., & Bonventre, J. V. (2020) · Kidney360 · doi:10.34067/kid.0002252020 · Cited by 35
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 36
Sim, R., Chong, C. W., Loganadan, N. K., Fong, A. Y. Y., Navaravong, L., Hussein, Z. B., Khunti, K., & Lee, S. W. H. (2021) · Diabetic Medicine · doi:10.1111/dme.14780 · Cited by 35
Sasaki, A., Yokote, K., Naitoh, T., Fujikura, J., Hayashi, K., Hirota, Y., Inagaki, N., Ishigaki, Y., Kasama, K., Kikkawa, E., et al. (2021) · Diabetology International · doi:10.1007/s13340-021-00551-0 · Cited by 36
Jeong, H. E., Park, S., Noh, Y., Bea, S., Filion, K. B., Yu, O. H. Y., Jang, S. H., Cho, Y. M., Yon, D. K., & Shin, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02765-2 · Cited by 32
Expectations in children with glomerular diseases from SGLT2 inhibitors
Cirillo, L., Ravaglia, F., Errichiello, C., Anders, H., Romagnani, P., & Becherucci, F. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05504-6 · Cited by 32
SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
Safaie, N., Masoumi, S., Alizadeh, S., Mirzajanzadeh, P., Nejabati, H. R., Hajiabbasi, M., Alivirdiloo, V., Basmenji, N. C., Radvar, A. D., Majidi, Z., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3922 · Cited by 32
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 36
Self-citationCardiovascular outcomes trials in type 2 diabetes: Time to include young adults
Ke, C., Shah, B. R., Luk, A. O. Y., Ruggiero, E. D., & Chan, J. C. N. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13874 · Cited by 31
Khunti, K. K., Kosiborod, M., Kim, D. J., Kohsaka, S., Lam, C. S. P., Goh, S., Chiang, C., Shaw, J. E., Cavender, M. A., Tangri, N., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01345-z · Cited by 30
Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering
Neuen, B. L., Cherney, D. Z. I., Jardine, M., & Perkovic, V. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190047 · Cited by 29
Self-citationScheen, A. J. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1733967 · Cited by 33
Kwak, S. H., Han, K. A., Kim, K., Yu, J. M., Kim, E.-S., Won, J. C., Kang, J. G., Chung, C. H., Oh, S., Choi, S. H., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15046 · Cited by 30
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius, F. C., Cherney, D. Z. I., Gee, P. O., Harris, R. C., Kliger, A. S., Tuttle, K. R., & Quaggin, S. E. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.18641120 · Cited by 28
Kumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
Lim, J., Hwang, I., Choi, H., Yoon, Y. E., & Cho, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269414 · Cited by 24
Rakic, D., Jakovljevic, V. L., Jović, N., Ilic, M. B., Dimitrijević, A., Vulovic, T. S., Arsenijević, P. S., Sretenovic, J. Z., Muric, M. D., Фисенко, В. П., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11040998 · Cited by 26
Neuen, B. L., Jardine, M., & Perkovic, V. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz252 · Cited by 26
Self-citationD’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 25
Kovesdy, C. P., Schmedt, N., Folkerts, K., Bowrin, K., Raad, H., Batech, M., & Fried, L. F. (2022) · BMC Medicine · doi:10.1186/s12916-021-02191-2 · Cited by 24
Raza, S., Osasan, S. A., Sethia, S., Batool, T., Bambhroliya, Z., Sandrugu, J., Lowe, M., Okunlola, O. I., & Hamid, P. (2022) · Cureus · doi:10.7759/cureus.26313 · Cited by 25
Renoprotective Effects of SGLT2 Inhibitors
Vallon, V. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.005 · Cited by 27
Real, J., Vlacho, B., Ortega, E., Vallés, J. A., Mata‐Cases, M., Castelblanco, E., Wittbrodt, E. T., Fenici, P., Kosiborod, M., Mauricio, D., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01323-5 · Cited by 26
New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling
Chen, Y., & Peng, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110072 · Cited by 28
Oikonomaki, D., Dounousi, E. C., Duni, Α., Roumeliotis, S. K., & Liakopoulos, V. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108604 · Cited by 25
Ivashkin, V. T., Drapkina, O. M., Maevskaya, M. V., Raikhelson, K. L., Okovityi, S. V., Жаркова, М. С., Grechishnikova, V. R., Abdulganieva, D. I., Alekseenko, S. A., Ardatskaya, M. D., et al. (2025) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2025-35-1-94-152 · Cited by 29
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14055 · Cited by 23
Lin, Y., Lin, C.-H., Huang, Y., Tai, A., Fu, S., Chen, S., & Lin, S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109816 · Cited by 23
Liaw, J., Harhay, M., Setoguchi, S., Gerhard, T., & Dave, C. V. (2022) · Diabetes Care · doi:10.2337/dc22-0224 · Cited by 21
The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes
O’Keefe, J. H., Nassif, M. E., MAGWIRE, M. L., O’Keefe, E. L., & Lavie, C. J. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.08.001 · Cited by 22
Kitazawa, T., Seino, H., Ohashi, H., Inazawa, T., Inoue, M., Ai, M., Fujishiro, M., Kuroda, H., Yamada, M., Anai, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14059 · Cited by 21
Xia, C., Han, Y., Yin, C., Geng, R., Liu, Z., Du, Y., & Yu, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1220516 · Cited by 23
Canagliflozin and Amputation Risk: Evidence So Far
Papadokostaki, E., Rizos, E. C., Tigas, S. K., & Liberopoulos, E. N. (2019) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734619878090 · Cited by 21
Mukai, J., Kanno, S., & Kubota, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-92925-2 · Cited by 20
Metadata
- Authors
- Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., & Perkovic, V.
- Affiliations
- UNSW Sydney (AU)
- The University of Sydney (AU)
- Concord Repatriation General Hospital (AU)
- Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen Groningen The Netherlands
- Royal North Shore Hospital (AU)
- Kyushu University (JP)
- Kanazawa University (JP)
- Corresponding author
- Perkovic, Vlado
- ORCID
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-03-04
- Volume
- 21
- Issue
- 5
- Pages
- 1237-1250
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2914038117
- Semantic Scholar
- c8cec90d787818b74940feb2baa18c4af10c6271
- Cited by
- 330
- References
- 104
- Citations by year
- 2026: 22 · 2025: 38 · 2024: 50 · 2023: 59 · 2022: 50 · 2021: 49 · 2020: 37 · 2019: 23
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Health and Medical Research Council of Australia
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, type 2 diabetes, chronic kidney disease, cardiovascular outcomes, renal outcomes, albuminuria, estimated glomerular filtration rate decline, heart failure, myocardial infarction, stroke, all-cause mortality, HbA1c, drug safety, drug interactions, adverse events, drug discontinuation, blood pressure, body weight
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diabetic Nephropathies, Humans, Hypoglycemic Agents, Treatment Outcome, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
